Page 40 - Exact Sciences News Today

Exact Sciences reported its sixth consecutive quarter of double-digit sales growth Tuesday, as EXAS stock continues its 10-month run. The post Exact Sciences,…

The first of a new wave of cancer-detection blood tests likely saved Gilbert Milam Jr.’s life. But many cancer researchers, wary of overtesting, argue it’s premature to prescribe the Galleri test widely.

The Nasdaq 100 closed higher on Friday. Investors, meanwhile, focused on some notable insider trades.

The guidance contradicts recommendations from other groups that lowered the starting age to 45.

Van ECK Associates Corp trimmed its position in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 15.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 167,782 shares of the medical research company’s stock after selling 30,116 shares during the quarter. Van ECK […]

TCI Wealth Advisors Inc. boosted its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 15,466.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 467 shares of the medical research company’s stock after acquiring an additional […]

Daiwa Securities Group Inc. boosted its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 10.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,602 shares of the medical research company’s stock after buying an additional 1,043 shares during the quarter. Daiwa […]

We kick off the second half of earnings season this week with reports from our last two mega-caps.

BTIG analyst Mark Massaro maintained a Buy rating on Guardant Health (GH – Research Report) yesterday and set a price target of $50.00. Th...